Hong Kong-listed AIM Vaccine (06660) schedules 30 March 2026 board meeting to approve FY2025 results and consider final dividend

Bulletin Express

Yesterday

The board of AIM Vaccine Co., Ltd. (Stock Code: 06660) has fixed Monday, 30 March 2026 for its next meeting. According to the company’s announcement filed with Hong Kong Exchanges and Clearing Limited, directors will review and approve the consolidated annual results for the financial year ended 31 December 2025. The agenda also includes discussion of a potential final dividend recommendation and other routine business matters.

The notice was issued by Chairman and CEO Mr. Yan Zhou on 18 March 2026. The current board comprises five executive directors—Mr. Yan Zhou, Mr. Xin Zhou, Mr. Shaojun Jia, Mr. Wen Guan and Mr. Jie Zhou—alongside one non-executive director, Mr. Jichen Zhao, and three independent non-executive directors, Professor Ker Wei Pei, Ms. Jie Wen and Mr. Xiaoguang Guo.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1182577465"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1182577465\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1182577465?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-18 16:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1182577465","market":"hk","top_or_hot":-1,"title":"Hong Kong-listed AIM Vaccine (06660) schedules 30 March 2026 board meeting to approve FY2025 results and consider final dividend","media":"Bulletin Express","content":"<p>The board of AIM Vaccine Co., Ltd. (Stock Code: 06660) has fixed Monday, 30 March 2026 for its next meeting. According to the company’s announcement filed with Hong Kong Exchanges and Clearing Limited, directors will review and approve the consolidated annual results for the financial year ended 31 December 2025. The agenda also includes discussion of a potential final dividend recommendation and other routine business matters.</p>\n<p>The notice was issued by Chairman and CEO Mr. Yan Zhou on 18 March 2026. The current board comprises five executive directors—Mr. Yan Zhou, Mr. Xin Zhou, Mr. Shaojun Jia, Mr. Wen Guan and Mr. Jie Zhou—alongside one non-executive director, Mr. Jichen Zhao, and three independent non-executive directors, Professor Ker Wei Pei, Ms. Jie Wen and Mr. Xiaoguang Guo.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hong Kong-listed AIM Vaccine (06660) schedules 30 March 2026 board meeting to approve FY2025 results and consider final dividend</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHong Kong-listed AIM Vaccine (06660) schedules 30 March 2026 board meeting to approve FY2025 results and consider final dividend\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-18 16:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>The board of AIM Vaccine Co., Ltd. (Stock Code: 06660) has fixed Monday, 30 March 2026 for its next meeting. According to the company’s announcement filed with Hong Kong Exchanges and Clearing Limited, directors will review and approve the consolidated annual results for the financial year ended 31 December 2025. The agenda also includes discussion of a potential final dividend recommendation and other routine business matters.</p>\n<p>The notice was issued by Chairman and CEO Mr. Yan Zhou on 18 March 2026. The current board comprises five executive directors—Mr. Yan Zhou, Mr. Xin Zhou, Mr. Shaojun Jia, Mr. Wen Guan and Mr. Jie Zhou—alongside one non-executive director, Mr. Jichen Zhao, and three independent non-executive directors, Professor Ker Wei Pei, Ms. Jie Wen and Mr. Xiaoguang Guo.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06660","symbol_name":"艾美疫苗","start_time":0,"source_url":"","article_id":"1182577465","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1182577465","pubTimestamp":1773823254,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"The board of AIM Vaccine Co., Ltd. (Stock Code: 06660) has fixed Monday, 30 March 2026 for its next meeting. According to the company’s announcement filed with Hong Kong Exchanges and Clearing...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06660":"艾美疫苗"},"translate_title":"香港上市AIM疫苗(06660)定于2026年3月30日召开董事会批准2025财年业绩并考虑末期股息","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06660":1},"content_text":"The board of AIM Vaccine Co., Ltd. (Stock Code: 06660) has fixed Monday, 30 March 2026 for its next meeting. According to the company’s announcement filed with Hong Kong Exchanges and Clearing Limited, directors will review and approve the consolidated annual results for the financial year ended 31 December 2025. The agenda also includes discussion of a potential final dividend recommendation and other routine business matters.\nThe notice was issued by Chairman and CEO Mr. Yan Zhou on 18 March 2026. The current board comprises five executive directors—Mr. Yan Zhou, Mr. Xin Zhou, Mr. Shaojun Jia, Mr. Wen Guan and Mr. Jie Zhou—alongside one non-executive director, Mr. Jichen Zhao, and three independent non-executive directors, Professor Ker Wei Pei, Ms. Jie Wen and Mr. Xiaoguang Guo.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"executive,SGX","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}